RT Journal Article
SR Electronic
T1 Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4026
DO 10.1183/13993003.congress-2019.PA4026
VO 54
IS suppl 63
A1 Jason Stokker
A1 Mina Karami
A1 Rogier A.S. Hoek
A1 Ditty Van Duijn
A1 Patricia Ormskerk
A1 Femke M. Muskens
A1 Joachim G.J.V. Aerts
A1 Diederik A.M.P.J. Gommers
A1 Menno M. van der Eerden
YR 2019
UL http://erj.ersjournals.com/content/54/suppl_63/PA4026.abstract
AB Rationale: Ventilator-associated pneumonia (VAP) is a common complication of mechanically ventilated patients. The relatively poor response rates seen with intravenous (IV) antibiotic (AB) therapy and the emergence of multidrug resistant microorganisms requires the development of new treatment strategies.Aim: To determine the effect of the adjunctive Tobramycin inhalation treatment in the treatment of VAP.Methods: A prospective double-blind randomized controlled trial was conducted. The treatment group received twice-daily Tobramycin inhalation 300 mg and standard IV AB therapy and the control group received twice daily placebo inhalation besides standard IV AB treatment. Primary outcome was treatment failure at day 4; secondary outcome parameters were mortality rate at day 30 and ventilation free days at day 28.Results: The study was terminated prematurely due to insufficient inclusion. The results of 26 included patients could be evaluated (treatment n=13, control n=13). Treatment failure was seen in 4 patients (31%) of the inhalation antibiotic group and in 8 patients (62%) of the control group (p=0.238). There was no difference in 30-day mortality rate between the groups (treatment group n=4 (31%) vs placebo group 4 patients (31%), [NS]). Number of ventilation free days at day 28 were 18 days [0-21] for the treatment group and 17 days [5-22] for the control group [NS].Conclusion: Although limited by a small sample size due to insufficient inclusion, the findings of our explorative randomized trial suggest that adjunctive Tobramycin inhalation therapy has no beneficial effect in the treatment of VAP.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4026.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).